Healthcare -
Biotechnology - NASDAQ - CA
$ 1.73
2.37 %
$ 76.8 M
Market Cap
-2.7
P/E
1. INTRINSIC VALUE
Balance Sheet
ESSA Pharma Inc.
| Current Assets | 128 M |
| Cash & Short-Term Investments | 127 M |
| Receivables | 163 K |
| Other Current Assets | 636 K |
| Non-Current Assets | 552 K |
| Long-Term Investments | 0 |
| PP&E | 295 K |
| Other Non-Current Assets | 257 K |
| Current Liabilities | 3.3 M |
| Accounts Payable | 2.4 M |
| Short-Term Debt | 124 K |
| Other Current Liabilities | 773 K |
| Non-Current Liabilities | 205 K |
| Long-Term Debt | 205 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
ESSA Pharma Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 21.2 M |
| Operating Income | -34.4 M |
| Other Expenses | -5.88 M |
| Net Income | -28.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ESSA Pharma Inc.
| Net Income | -28.5 M |
| Depreciation & Amortization | 90.7 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 6.54 M |
| Change in Working Capital | -419 K |
| Others | -712 K |
| Free Cash Flow | -22.7 M |
Wall Street Analysts Price Targets
ESSA Pharma Inc.
Wall Street analysts predict an average 1-year price target for EPIX of $11.3 , with forecasts ranging from
a
low of
$2 to a high of $17 .
EPIX Lowest Price Target
Wall Street Target
2 USD
15.61%
EPIX Average Price Target
Wall Street Target
11.3 USD
555.11%
EPIX Highest Price Target
Wall Street Target
17 USD
882.66%
4. DIVIDEND
ANALYSIS
EPIX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
ESSA Pharma Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
12 M USD 1
9-12 MONTHS
16.7 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025
Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025.
prnewswire.com
- 1 month ago
Shareholders of ESSA Pharma Inc. Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138642&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 2 months ago
ESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX
NEW YORK , March 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024.
prnewswire.com
- 2 months ago
EPIX Deadline Today: Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of ESSA Pharma Inc. (NASDAQ: EPIX) securities between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”). The lawsuit describes ESSA as a “clinical stage pharmaceutical company that focuses on the development of small molecular drugs for the treatment of prostate cancer.” For more information, submit a form, ema.
businesswire.com
- 2 months ago
ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138572&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 2 months ago
EPIX DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - EPIX
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ:EPIX) between December 12, 2023 and October 31, 2024, inclusive (the "Class Period"), of the important March 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased ESSA Pharma Inc. securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
accessnewswire.com
- 2 months ago
Investors who lost money on ESSA Pharma Inc.(EPIX) should contact Levi & Korsinsky about pending Class Action - EPIX
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138559&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 2 months ago
FINAL REMINDER EPIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts ESSA Pharma Inc. Investors to Participate in the Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period").
accessnewswire.com
- 2 months ago
ESSA Pharma Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – EPIX
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138426&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 3 months ago
ESSA Pharma Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion
Investors can contact the law firm at no cost to learn more about recovering their losses
globenewswire.com
- 3 months ago
EPIX LAWSUIT ALERT: Levi & Korsinsky Notifies ESSA Pharma Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138382&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 3 months ago
Shareholders of ESSA Pharma Inc. Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138345&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 3 months ago
8. Profile
Summary
ESSA Pharma Inc. EPIX
COUNTRY
CA
INDUSTRY
Biotechnology
MARKET CAP
$ 76.8 M
Dividend Yield
0.00%
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Contact
999 West Broadway, Vancouver, BC, V5Z 1K5
https://www.essapharma.com
IPO
Date
March 13, 2015
Employees
35
Officers
Dr. Alessandra Cesano M.D., Ph.D.
Chief Medical Officer & Executive Vice President
Chandtip Chandhasin
Executive
Erin Rudsinski
Executive
Nkengyal Barber
Executive
Erica Osbourne
Executive
Neil Thapar
Executive
Loleta Harris
Executive
Dr. David Ross Parkinson M.D.
President, Chief Executive Officer & Director
Mr. Peter A. Virsik M.B.A., M.S.
Executive Vice President & Chief Operating Officer
Mr. David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA
Chief Financial Officer